Sugi Predict

Sugi Predict / Targets / KRAS

KRAS

GTPase KRas · P01116 · KRAS on Sugi Atlas →

225,039 patent compounds predicted against KRAS, 136,017 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL111255 SCHEMBL111255 0.64 13/20
SCHEMBL110999 SCHEMBL110999 0.63 13/20
SCHEMBL112343 SCHEMBL112343 0.65 12/20
SCHEMBL109112 SCHEMBL109112 0.64 11/20
SCHEMBL111938 SCHEMBL111938 0.50 11/20
SCHEMBL723267 SCHEMBL723267 0.50 11/20
SCHEMBL161814 SCHEMBL161814 0.49 11/20
SCHEMBL112114 SCHEMBL112114 0.52 10/20
SCHEMBL109875 SCHEMBL109875 0.49 10/20
Phosphoramidic Acid Phosphoramidic Acid (SCHEMBL112033) 0.49 9/20
Phosphoramidic Acid Phosphoramidic Acid (SCHEMBL108470) 0.48 9/20
SCHEMBL407395 SCHEMBL407395 0.69 8/20
SCHEMBL401416 SCHEMBL401416 0.64 8/20
SCHEMBL442292 SCHEMBL442292 0.57 8/20
SCHEMBL180928 SCHEMBL180928 0.55 8/20
SCHEMBL112103 SCHEMBL112103 0.48 8/20
SCHEMBL574773 SCHEMBL574773 0.67 7/20
SCHEMBL599196 SCHEMBL599196 0.59 7/20
SCHEMBL418013 SCHEMBL418013 0.51 7/20
SCHEMBL609239 SCHEMBL609239 0.47 7/20

Clinical trials — most relevant to KRAS by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer PHASE3ACTIVE_NOT_RECRUITING
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS PHASE2RECRUITING
PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine) PHASE2COMPLETED
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS PHASE1/PHASE2RECRUITING
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery PHASE2COMPLETED
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) PHASE2RECRUITING
Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations PHASE2COMPLETED
SBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer PHASE2COMPLETED
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC PHASE1/PHASE2RECRUITING
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer PHASE1/PHASE2RECRUITING
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation PHASE1/PHASE2RECRUITING
A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation PHASE1/PHASE2RECRUITING
Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab PHASE2WITHDRAWN
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation PHASE1/PHASE2COMPLETED
A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations PHASE1/PHASE2RECRUITING
New Individualized Therapy Trial for Metastatic Colorectal Cancer PHASE1/PHASE2COMPLETED
Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies PHASE1RECRUITING
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer PHASE1ACTIVE_NOT_RECRUITING
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors PHASE1RECRUITING
Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas PHASE1COMPLETED
Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation PHASE1ACTIVE_NOT_RECRUITING
Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients PHASE1UNKNOWN
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma PHASE1ACTIVE_NOT_RECRUITING
A Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation PHASE1UNKNOWN
Multicentric Database for KRAS Mutant Pancreatic Cancer nanRECRUITING
Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma nanAVAILABLE
DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit nanRECRUITING
KRAS Mutation and Incidence of the Colorectal Carcinoma in Martinique Between 2007 and 2009 nanCOMPLETED
Studying Pathways of Resistance in KRAS-driven Cancers nanACTIVE_NOT_RECRUITING
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a KRAS binder may also engage these)

ProteinNameSimilarity
P08644 — 1.000 P08644 →
P32883 — 1.000 P32883 →
P05774 — 1.000 P05774 →
P01117 — 1.000 P01117 →
Q95ME4 — 1.000 Q95ME4 →
Q2MJK3 — 1.000 Q2MJK3 →
P20171 — 1.000 P20171 →
NRAS GTPase NRas 1.000 landscape →
P08642 — 1.000 P08642 →
P12825 — 0.999 P12825 →
Q5F352 — 0.999 Q5F352 →
HRAS GTPase HRas 0.998 landscape →
Q05147 — 0.998 Q05147 →
P79737 — 0.998 P79737 →
P23175 — 0.997 P23175 →
P83831 — 0.997 P83831 →
P01113 — 0.997 P01113 →
Q04970 — 0.997 Q04970 →
Q61411 — 0.997 Q61411 →
Q5EFX7 — 0.996 Q5EFX7 →
Q5RD87 — 0.996 Q5RD87 →
B4GFJ8 — 0.996 B4GFJ8 →
P08556 — 0.995 P08556 →
B4LY29 — 0.995 B4LY29 →
Q91806 — 0.995 Q91806 →
P08646 — 0.995 P08646 →
B4PUP5 — 0.995 B4PUP5 →
B3NZR4 — 0.995 B3NZR4 →
P83832 — 0.995 P83832 →
B3M185 — 0.995 B3M185 →